2018年4月1日
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis
Experimental Dermatology
- ,
- ,
- 巻
- 27
- 号
- 4
- 開始ページ
- 327
- 終了ページ
- 331
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1111/exd.13533
- 出版者・発行元
- Blackwell Publishing Ltd
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell-mediated immunity. Interleukin (IL)-31 is a potent pruritogenic cytokine primarily produced by Th2 cells. Both IL-31 transgenic mice and wild-type mice treated with IL-31 exhibit AD-like skin lesions and scratching behaviour. IL-31 receptor α-chain (IL-31RA) is also expressed in peripheral nerves and epidermal keratinocytes, and the roles of IL-31 on pruritus and skin barrier have been investigated. Recently, an anti–IL-31 receptor antibody was shown to significantly improve pruritus in AD patients. This review focuses on IL-31 and IL-31RA in AD.
- ID情報
-
- DOI : 10.1111/exd.13533
- ISSN : 1600-0625
- ISSN : 0906-6705
- PubMed ID : 29524262
- SCOPUS ID : 85046551038